CAS 389574-19-0
:Prasugrel hydrochloride
Description:
Prasugrel hydrochloride is an antiplatelet medication primarily used to reduce the risk of cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. It is a thienopyridine derivative that acts as a prodrug, requiring metabolic activation to exert its pharmacological effects. The active metabolite irreversibly binds to the P2Y12 receptor on platelets, inhibiting ADP-mediated platelet activation and aggregation. This characteristic makes prasugrel more potent and faster-acting compared to some other antiplatelet agents. The hydrochloride salt form enhances its solubility and stability. Prasugrel is typically administered orally and is known for its favorable pharmacokinetic profile, including a rapid onset of action and a relatively short half-life. Common side effects may include bleeding complications, which necessitate careful patient selection and monitoring. Due to its mechanism of action, prasugrel is contraindicated in patients with a history of transient ischemic attacks or strokes. Overall, prasugrel hydrochloride is a critical therapeutic option in the management of acute coronary syndromes.
Formula:C20H20FNO3S·ClH
InChI:InChI=1S/C20H20FNO3S.ClH/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21;/h2-5,10,13,19H,6-9,11H2,1H3;1H
InChI key:InChIKey=JALHGCPDPSNJNY-UHFFFAOYSA-N
SMILES:C(C(=O)C1CC1)(N2CC3=C(CC2)SC(OC(C)=O)=C3)C4=C(F)C=CC=C4.Cl
Synonyms:- 2-Acetoxy-5-(α-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine hydrochloride
- 2-[2-(Acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)ethanone hydrochloride
- 5-[2-Cyclopropyl-1-(2-Fluorophenyl)-2-Oxoethyl]-4,5,6,7-Tetrahydrothieno[3,2-C]Pyridin-2-Yl Acetate Hydrochloride (1:1)
- Effient
- Efient
- Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, hydrochloride
- Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, hydrochloride (1:1)
- Prasu Doc
- Prasugrel hydrochloride
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 10 products.
Prasugrel Hydrochloride (5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate hydrochloride)
CAS:Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds, nesoiFormula:C20H20FNO3S·HClColor and Shape:White Off-White PowderMolecular weight:409.09147Ethanone, 2-[2-(acetyloxy)-6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl]-1-cyclopropyl-2-(2-fluorophenyl)-, hydrochloride (1:1)
CAS:Formula:C20H21ClFNO3SPurity:99%Color and Shape:SolidMolecular weight:409.9020Prasugrel Hydrochloride
CAS:Controlled ProductFormula:C20H20FNO3S·ClHColor and Shape:NeatMolecular weight:409.90Prasugrel Hydrochloride
CAS:<p>Prasugrel Hydrochloride (LY 640315 Hydrochloride) is pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome.</p>Formula:C20H20FNO3S·HClPurity:99.39% - 99.79%Color and Shape:SolidMolecular weight:409.9Prasugrel hydrochloride
CAS:Formula:C20H20FNO3S·HClPurity:98.0 - 102.0 % (dried basis)Color and Shape:White to off-white powderMolecular weight:409.90Prasugrel Hydrochloride
CAS:Controlled Product<p>Applications A novel antiplatelet agent; it is a third-generation thienopyridine. Antiplatelet agent Prasugrel showed greater platelet inhibition and decreased incidence of ischemic events than Clopidogrel but may induce increased incidence of bleeding in patient with acute coronary syndrome<br>References Von Beckerath, N., et al.: Circulation, 112, 2946 (2005), Jernberg, T., et al.: Eur. Heart J., 27, 1166 (2006), Farid, N., et al.: Drug Metab. Dispos., 35, 1096 (2007), Farid, N., et al.: Clin. Pharmacol. Ther., 81, 735 (2007), Jakubowski, J., et al.: J. Cardiovasc. Pharmacol., 49, 167 (2007), Wiviott, S., et al.: N. Engl. J. Med., 357, 2001 (2007),<br></p>Formula:C20H20FNO3S·ClHColor and Shape:NeatMolecular weight:409.90









